sclcMAD11162_S44.txt
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.420
- COAGULATION+0.350
- MYOGENESIS+0.340
- INFLAMMATORY_RESPONSE+0.280
- APICAL_SURFACE+0.260
- TNFA_SIGNALING_VIA_NFKB+0.210
- BILE_ACID_METABOLISM+0.190
- XENOBIOTIC_METABOLISM+0.180
- IL6_JAK_STAT3_SIGNALING+0.170
- ANGIOGENESIS+0.150
Top 10 suppressed
- MYC_TARGETS_V1-0.710
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.650
- OXIDATIVE_PHOSPHORYLATION-0.610
- MYC_TARGETS_V2-0.600
- DNA_REPAIR-0.550
- MTORC1_SIGNALING-0.540
- PROTEIN_SECRETION-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.530
- MITOTIC_SPINDLE-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-AARR-01A-11R-A41B-07 | — | cohortA1 | 0.966 |
| 2 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.950 |
| 3 | BS_YZ2Z1Q6Y | pilocytic astrocytoma | — | 0.940 |
| 4 | SRR1415732 | GTEX | — | 0.937 |
| 5 | SRR1444876 | GTEX | — | 0.936 |
| 6 | SRR1500428 | GTEX | — | 0.933 |
| 7 | BS_VTJ9ESSV | DNET | — | 0.930 |
| 8 | SRR1352554 | GTEX | — | 0.928 |
| 9 | BS_GTZCFGRZ | Ganglioglioma | — | 0.928 |
| 10 | 525b66e0-235a-4bf5-bc46-eb022d630115 | — | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |